After surviving a sales and profit dip from the loss of exclusivity for its top product, Daiichi Sankyo Co. Ltd. is aiming to expand its group revenues by JPY120bn ($1.10bn) over the next five years under a new mid-term business plan, helped by a strategic focus on oncology.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?